AKBA Crosses Above Average Analyst Target
October 02, 2017 at 09:14 AM EDT
In recent trading, shares of Akebia Therapeutics Inc (AKBA) have crossed above the average analyst 12-month target price of $19.25, changing hands for $19.67/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..